LAMEA IVD In Cardiology And Neurology Market Size, Share & Trends Analysis Report By Product Type, By End Use, By Technology (Immunoassays, Molecular Diagnostics, Hematology, and Others), By Country and Growth Forecast, 2023 - 2030

The LAMEA IVD In Cardiology And Neurology Market would witness market growth of 12.1% CAGR during the forecast period (2023-2030).

The Brazil market dominated the LAMEA IVD In Cardiology And Neurology Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $562.5 million by 2030. The Argentina market is showcasing a CAGR of 12.7% during (2023 - 2030). Additionally, The UAE market would register a CAGR of 11.7% during (2023 - 2030).



Incorporating genomics into intravenous disease (IVD) tests facilitates accurate risk stratification, empowering medical professionals to detect individuals more susceptible to the onset of cardiovascular or neurological ailments. This information empowers clinicians to tailor preventive strategies, lifestyle recommendations, and therapeutic interventions based on an individual's genetic predispositions. Personalized treatment plans enhance the efficacy of interventions, leading to more targeted and efficient patient care.

Furthermore, liquid biopsy, a non-invasive diagnostic approach, is gaining traction in neurology. This innovative technique involves analyzing circulating biomarkers, such as DNA, RNA, or proteins, in the bloodstream. In neuro-oncology, liquid biopsy is promising for early cancer detection, treatment response monitoring, and minimal residual disease detection. By identifying specific genetic mutations or alterations associated with brain tumors, liquid biopsy enables clinicians to detect the presence of cancerous cells at an early stage. Early detection is crucial for timely interventions and improved patient outcomes.

Middle East has witnessed an increase in cardiovascular disease (CVD) cases over recent years. As per the National Library of Medicine, the Middle East has a high rate of cardiovascular disease (10.1%). In this region, the prevalence of dyslipidemia (43.3%) is double that of hypertension (26.2%) and diabetes mellitus (16%). Multifaceted interventions are desperately needed in this region for CVD primary prevention. Hence, the rising number of cardiovascular disease cases and healthcare sector growth in LAMEA will assist in the growth of the regional market.

Based on Product Type, the market is segmented into Reagents & Consumables, Instruments, and Software & Services. Based on End Use, the market is segmented into Hospitals, Clinical Laboratories, and Others. Based on Technology, the market is segmented into Immunoassays, Molecular Diagnostics, Hematology, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

List of Key Companies Profiled

• Thermo Fisher Scientific, Inc.
• F.Hoffmann-La Roche Ltd.
• Sysmex Corporation
• Siemens Healthineers AG (Siemens AG)
• Quest Diagnostics Incorporated
• Abbott Laboratories
• Bio-Rad Laboratories, Inc.
• Danaher Corporation (Beckman Coulter, Inc.)
• Becton, Dickinson and Company
• Natera, Inc.

Market Report Segmentation

By Product Type

• Reagents & Consumables
• Instruments
• Software & Services

By End Use

• Hospitals
• Clinical Laboratories
• Others

By Technology

• Immunoassays
• Molecular Diagnostics
• Hematology
• Others

By Country

• Brazil
• Argentina
• UAE
• Saudi Arabia
• South Africa
• Nigeria
• Rest of LAMEA